Ask AI
ProCE Banner Activity

CASSANDRA PACT-21: Randomized, Phase III Trial of Preoperative Chemotherapy With mFOLFIRINOX or PAXG for Stage I-III PDAC

Conference Coverage
Slideset

In the randomized phase III CASSANDRA PACT-21 trial, the PAXG regimen improved EFS vs FOLFIRINOX and showed a manageable safety profile in the preoperative setting in patients with stage I-III resectable or borderline resectable pancreatic ductal adenocarcinoma.

Released: June 09, 2025

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group